Valaciclovir prophylaxis versus preemptive valganciclovir for the prevention of cytomegalovirus inclusion disorders in renal transplant recipients

Trial Profile

Valaciclovir prophylaxis versus preemptive valganciclovir for the prevention of cytomegalovirus inclusion disorders in renal transplant recipients

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Valaciclovir (Primary) ; Valganciclovir
  • Indications Cytomegalic inclusion disorders
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 04 May 2011 Long-term results presented at the American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top